09:01 AM EST, 11/12/2024 (MT Newswires) -- CG Oncology ( CGON ) reported a Q3 loss Tuesday of $0.30 per diluted share, narrower than a loss of $4 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.38.

As expected, no revenue for the quarter ended Sept. 30 was reported.

As of Sept. 30, cash, cash equivalents and marketable securities were $540.7 million, which is expected to support operations through 2027, the company said.